TABLE 3.

Comparison of MALDI-TOF MS, INNOLiPA DR, and direct sequencing in detection of HBV drug-resistant variants in selected treatment-naive and experienced patients

Patient no.	Therapy experience	Drug-resistant variant(s) found with the indicated method of HBV reverse transcriptase polymorphism detection
		MALDI-TOF MS	INNOLiPA HBV DR	Direct sequencing
21	Experienced	L180M, T184S, M204I, I233V	L180M, M204V	WTa
23	Experienced	L80I, V173L, A 181 T, M204I, I233V, M250V	M204I	WT
28	Experienced	L80V, V173L, L180M, M204V, I233V, M250V	L180M, M204V	WT
30	Naive	L80I, M204V, I233V	WT	WT
32	Experienced	L80I, L180M, A181T, M204V	WT	WT
101	Naive	L80I, N236T	WT	WT
115	Naive	N236T	WT	WT
119	Naive	I233V, M250V	WT	WT
124	Experienced	L80I, N236T	WT	WT
125	Naive	I233V, I250V	WT	WT
126	Experienced	L180M, A181T, M204V, I233V, M250V	L80 M, M204V	WT
127	Naive	L80I, V173L, I233V, M250V	WT	WT
133	Naive	L80I, M204I	WT	WT
134	Experienced	I169P, L180M, T184A, M204V	M204V, L180M	WT
143	Experienced	L80I, L180M, A181T, M204I, I233V	L80I, M204I	WT

^aWT, wild type of HBV.